Crossmark

Genome-wide association study identifies novel loci for type 2 diabetes-attributed end-stage kidney disease in African Americans

Crossref DOI link: https://doi.org/10.1186/s40246-019-0205-7

Published Online: 2019-05-15

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

,

Guan, Meijian

Keaton, Jacob M.

Dimitrov, Latchezar

Hicks, Pamela J.

Xu, Jianzhao

Palmer, Nicholette D.

Ma, Lijun

Das, Swapan K.

Chen, Yii-Der I.

Coresh, Josef

Fornage, Myriam

Franceschini, Nora

Kramer, Holly

Langefeld, Carl D.

Mychaleckyj, Josyf C.

Parekh, Rulan S.

Post, Wendy S.

Rasmussen-Torvik, Laura J.

Rich, Stephen S.

Rotter, Jerome I.

Sedor, John R.

Thornley-Brown, Denyse

Tin, Adrienne

Wilson, James G.

Freedman, Barry I.

Bowden, Donald W.

Ng, Maggie C. Y.
Funding

Funding for this research was provided by:

National Institutes of Health (HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700004I, HHSN268201700005I, R01HL087641, R01HL086694, U01HG004402, HHSN268200625226C, UL1RR025005, HHSN268201300025C, HHSN268201300026C, HHSN268201300027C, HHSN268201300028C, HHSN268201300029C, HHSN268200900041C, AG0005, N01-HC-65226, U01DK57292, U01DK57329, U01DK057300, U01DK057298, U01DK057249, U01DK57295, U01DK070657, U01DK057303, U01DK070657, U01DK57304, DK07024, HHSN268201300049C, HHSN268201300050C, HHSN268201300048C, HHSN268201300046C, HHSN268201300047C, HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-000040, UL1-TR-001079, UL1-TR-001420, UL1-TR-001881, DK063491, N02-HL-64278, UL1TR001881, DK063491, HHSC268200782096C, DK081350, DK066358, DK053591, DK087914, DK105556, HL56266, DK070941)

Wake Forest School of Medicine (M01 RR07122)
License Information

Text and Data Mining valid from 2019-05-15

Version of Record valid from 2019-05-15
More Information

Article History

Received: 21 December 2018

Accepted: 11 April 2019

First Online: 15 May 2019

Ethics approval and consent to participate

: Analyses were approved by local institutional review boards, and all participants provided written informed consent.

: Not applicable.

: Wake Forest University Health Sciences and Barry Freedman have rights to an issued US patent related to <i>APOL1</i> gene testing. Dr. Freedman is a consultant for Ionis and AstraZeneca Pharmaceuticals.The other authors declare that they have no competing interests.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below